Can Abbott’s Connected Neuromodulation Platforms Improve Life For...

Why It Matters

Connected neuromodulation platforms enable personalized, data‑driven therapy that can improve patient outcomes while opening growth opportunities for Abbott in the expanding digital health market.

Key Takeaways

• Abbott’s neuromodulation platforms integrate wireless connectivity for personalized therapy.
• AI acts as “GPS” guiding clinicians in device programming decisions.
• Patient‑centric design aims to reduce burden while enhancing outcomes.
• Collaboration with partners like Confluent advances neurovascular material innovations.
• Real‑world stories illustrate impact on chronic pain and Parkinson’s patients.

Summary

The latest Abbott Talks podcast episode spotlights Abbott’s connected neuromodulation platform, a suite of implantable devices that communicate wirelessly with clinicians, electronic health records and AI‑driven decision tools. Host Tom Salmi and guests, including R&D vice‑president Rebecca Wilkins, discuss how the technology is built to fit seamlessly into a patient’s life, from leadless pacemakers to MRI‑compatible neurostimulation systems, and how it aligns with Abbott’s broader “systems of care” strategy. Key insights include the use of artificial intelligence as a “GPS” for programming neuromodulation therapy, the push for MRI‑compatible implants that eliminate a historic safety barrier, and the partnership with Confluent Medical to leverage advanced polymer tubing and film‑cast materials for tighter neurovascular tolerances. The conversation also revisits earlier season highlights—leadless pacemakers, temporary heart pumps, and AI‑enabled diagnostics—underscoring a consistent theme of devices that talk to each other inside the body. Memorable moments feature Ethan Cornold’s AI‑GPS analogy, Rebecca Wilkins’ personal story about helping her mother manage Parkinson’s with Abbott’s neurostimulation system, and the hosts’ recurring “holy moly” reactions to breakthroughs. These anecdotes humanize the technology and illustrate real‑world impact on chronic pain, movement disorders and heart failure patients. The episode signals a shift toward fully integrated, data‑rich therapeutic ecosystems that promise better outcomes, lower procedural risk and new revenue streams for Abbott. For clinicians, insurers and investors, the message is clear: connected neuromodulation is moving from niche innovation to a cornerstone of modern, value‑based care.

Original Description

In the final episode of AbbottTalks season 3, hosts Tom Salemi and Kayleen Brown sit down with Rebecca Wilkins, divisional vice president of R&D for Abbott’s Neuromodulation business, to discuss the technologies Abbott is advancing for chronic pain and movement disorders.

Wilkins explains how Abbott’s spinal cord stimulation platforms, Proclaim™ DRG Neurostimulation System, and Infinity™ deep brain stimulation system are designed to interrupt errant nervous system signals, helping patients manage conditions ranging from chronic pain and Parkinson’s disease to, potentially, treatment-resistant depression.

The conversation also highlights the features shaping Abbott’s neuromodulation portfolio, including Bluetooth-enabled connectivity, the NeuroSphere™ Virtual Clinic for remote programming, improved MRI compatibility including prone MRI access, and device options that balance small size with low recharge demands.

Wilkins also shares new data presented at NANS showing significant reductions in pain-related healthcare encounters for patients using Abbott’s spinal cord stimulation and DRG therapies.

***

Enjoy this podcast? Follow AbbottTalks on all major podcast players: https://abbotttalks.castos.com/ Subscribe + Follow us on [YouTube.com/@DeviceTalks](https://www.youtube.com/@DeviceTalks) to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe